Medicines constitute a significant cost component of modern healthcare systems across the world. However, in India the situation is even worse, where as per recent studies, drugs contribute as high as around 70 percent of the total treatment cost. This … Continue reading
Tag Archives: for
The Concept of Orphan Drugs for Orphan Diseases is Orphan in India
Though the percentage of patients suffering from ‘Rare Diseases’ in India is reportedly higher than the world average, unfortunately even today such cases get little help from our government. According to experts, diseases manifesting patients representing maximum 6 to 8 … Continue reading
The ruckus over Clinical Trials in India compels Government tightening regulations before flooring gas pedal for regional leadership
The subject of Clinical Trials in India has created a huge ruckus, mainly for wide spread alleged malpractices, abuse and misuse of the fragile regulations of the country by the players in this field. The issue is not just of … Continue reading
‘Free Essential Medicines for All’ – A Laudable Public Healthcare Initiative of India, Tough Challenges Notwithstanding
Recently the Government of India has taken a landmark ‘Public Healthcare’ related initiative to provide unbranded generic formulations of all essential drugs, featuring in the ‘National List of Essential Medicines 2011’, free of cost to all patients from the public … Continue reading
Chasing the “Holy Grail”: Reasonably affordable healthcare for all
The Healthcare industry of the world as a whole with a size of several trillion US$ is growing at a fast pace in many countries for various reasons. The industry can be broadly divided into six categories as follows: Managed … Continue reading
Grant of Compulsory License for Bayer’s Nexavar in India raises more questions than answers
On March 12, 2012, the Patent Office of India, in its landmark ruling, granted its first ever Compulsory License (CL) for Bayer’s patented kidney and liver cancer drug Nexavar (Sorafenib), to the generic pharma player Natco, broadly citing the following … Continue reading
Arresting continuous job losses in the global pharma industry call for innovation across the value chain
In not too distant past, the stocks of the global pharmaceutical companies, by and large, used to be categorized as ‘blue-chips’ for their high return to investors, as compared to many other sectors. Unfortunately, the situation has changed significantly since … Continue reading
Quantum Growth Envisaged in Government Procurement for Pharmaceuticals: A Challenging Ball Game for Pharma Players
Direct procurement by the Governments of various countries is attracting increasing importance not just at the domestic level, but internationally, as well. The systems adopted for Government Procurement (GP) globally are aimed at making a significant difference in the effectiveness … Continue reading